Spectral Medical Inc. (EDT.TO) has seen a slight decline in its stock price this week amidst various updates regarding its clinical trials and regulatory submissions.
This week, Spectral Medical Inc. experienced a minor decrease in stock performance, closing at C$1.38. With no significant news announced recently, investors are closely watching the company's ongoing developments and technical indicators.
Advertisement
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeAdvertisement
Market cap
$407.85M
52W high
$1.84
52W low
$0.97
1W change
-1.42%
Beta
0.21
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 126.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+126.6% Upside
Current Price
C$1.39
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
27.0%
Annualized
90-Day Vol
28.5%
Annualized
Trend (90d)
-6.0%
Annualized drift
90d Mean
C$1.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.38 | C$1.26 – C$1.51 |
| 60 trading days | C$1.37 | C$1.20 – C$1.56 |
| 90 trading days | C$1.36 | C$1.16 – C$1.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors in Spectral Medical should pay attention to the company's recent regulatory activities and trial results while monitoring technical indicators that suggest a stable trading range.
Stock Performance Overview
Spectral Medical's stock has declined by 1.42% this week, with a year-to-date increase of just 0.72%.
Bull case
The recent filing of the PMA application for the PMX device, along with promising trial results, could set Spectral Medical up for significant growth if the FDA approves its application.
Bear case
Concerns about the company's financial health arise from its negative return on equity and lack of profitability, which could affect its ability to sustain operations in a competitive healthcare market.
Recent Stock Performance
Spectral Medical Inc.'s stock closed at C$1.38, showing no change in price for the day. Over the past week, the stock has decreased by 1.42%, while it has increased by 2.96% month-to-date and 0.72% year-to-date. The trading volume for the latest session was 44,018 shares, which is about 71% of the 20-day average volume of 56,281 shares.
Company Developments
Advertisement
Despite no major news this week, there have been significant developments in recent months. Notably, on June 25, 2026, Spectral Medical announced the filing of a Premarket Approval (PMA) application for its PMX device with the U.S. FDA. This filing is crucial as it could pave the way for commercialization if approved. Additionally, the results from the Tigris trial indicated a 13.9% absolute risk reduction in mortality rates with PMX compared to standard care, highlighting the device's potential efficacy.
Technical Picture
From a technical perspective, Spectral Medical is currently trading slightly above its 50-day moving average of C$1.37 and its 200-day moving average of C$1.36, suggesting a stable price range. The stock has a 52-week trading range of C$0.97 to C$1.84, indicating that it is currently at 47% of its range. The stock's beta is low at 0.21, indicating lower volatility compared to the broader market.
Insider Activity
No recent insider activity has been reported for Spectral Medical Inc., which may suggest a stable internal outlook among company executives.
Conclusion
In summary, Spectral Medical Inc. (EDT.TO) closed at C$1.38, with a 1D change of 0.00%. Investors should keep a close eye on upcoming developments, especially regarding the FDA's review of the PMA application and the company's ongoing clinical trials.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
